Rafael Holdings, Inc.

NYSE RFL

Rafael Holdings, Inc. Current Liabilities for the quarter ending October 31, 2024

Rafael Holdings, Inc. Current Liabilities is NA for the quarter ending October 31, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Rafael Holdings, Inc. Current Liabilities for the quarter ending October 31, 2023 was USD 934.00 K, a -70.87% change year over year.
Rafael Holdings, Inc. Current Liabilities for the quarter ending October 31, 2022 was USD 3.21 M, a -81.43% change year over year.
Rafael Holdings, Inc. Current Liabilities for the quarter ending October 31, 2021 was USD 17.26 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NYSE: RFL

Rafael Holdings, Inc.

CEO	Mr. William Conkling
IPO Date	March 27, 2018
Location	United States
Headquarters	520 Broad Street
Employees	13
Sector	Real Estate
Industries Health Care REITs Office REITs

Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key trends

Past 5 years